These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34742474)

  • 1. Thyroid disorders associated with immune control point inhibitors.
    Fidilio E; Navarro-González E; Romero-Lluch AR; Iglesias P; Diez Gómez JJ; Anda Apiñániz E; Santos Mazo E; Zafón C
    Endocrinol Diabetes Nutr (Engl Ed); 2021; 68(6):408-415. PubMed ID: 34742474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
    Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
    Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
    Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
    Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-induced thyroid dysfunction in patients with lung cancer.
    Ramos-Levi AM; Rogado J; Sanchez-Torres JM; Colomer R; Marazuela M
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Jan; 66(1):26-34. PubMed ID: 29910159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
    Zhou Y; Xia R; Xiao H; Pu D; Long Y; Ding Z; Liu J; Ma X
    Int Immunopharmacol; 2021 Feb; 91():107296. PubMed ID: 33360368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study.
    Kennedy OJ; Ali N; Lee R; Monaghan P; Adam S; Cooksley T; Lorigan P
    Eur J Cancer; 2024 May; 202():113949. PubMed ID: 38432099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes.
    García-Goñi M; Vázquez Gutiérrez B; Sanmamed MF; Martín-Algarra S; Luis Pérez-Gracia J; Olmedo M; Chumbiauca E; Martín-Calvo N; Galofré JC
    Endocr Relat Cancer; 2024 Oct; 31(10):. PubMed ID: 39013402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis.
    Yang P; Shen G; Zhang H; Zhang C; Li J; Zhao F; Li Z; Liu Z; Wang M; Zhao J; Zhao Y
    Int Immunopharmacol; 2024 May; 133():111961. PubMed ID: 38608442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?
    Sbardella E; Tenuta M; Sirgiovanni G; Gianfrilli D; Pozza C; Venneri MA; Cortesi E; Marchetti P; Lenzi A; Gelibter AJ; Isidori AM
    Clin Endocrinol (Oxf); 2020 Mar; 92(3):258-265. PubMed ID: 31788837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid Dysfunction in Non-Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta-Analysis.
    Lin L; Yang F; Lin G; Chen X
    J Clin Pharmacol; 2023 Feb; 63(2):210-218. PubMed ID: 36083133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes.
    Peiró I; Palmero R; Iglesias P; Díez JJ; Simó-Servat A; Marín JA; Jiménez L; Domingo-Domenech E; Mancho-Fora N; Nadal E; Villabona C
    Endocrine; 2019 Jun; 64(3):605-613. PubMed ID: 30805887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
    Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
    J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab.
    Kimbara S; Fujiwara Y; Iwama S; Ohashi K; Kuchiba A; Arima H; Yamazaki N; Kitano S; Yamamoto N; Ohe Y
    Cancer Sci; 2018 Nov; 109(11):3583-3590. PubMed ID: 30230649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitor-induced hypothyroidism predicts treatment response in Japanese subjects.
    Iwamoto Y; Kimura T; Dan K; Ohnishi M; Takenouchi H; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
    Front Endocrinol (Lausanne); 2023; 14():1221723. PubMed ID: 37583431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitor-induced Thyroid Disorders: A Single Center Experience.
    Patrizio A; Fallahi P; Antonelli A; Ferrari SM
    Curr Pharm Des; 2023; 29(4):295-299. PubMed ID: 35593347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
    Chmielewska I; Dudzińska M; Szczyrek M; Świrska J; Wojas-Krawczyk K; Zwolak A
    PLoS One; 2021; 16(9):e0257484. PubMed ID: 34587185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
    Almutairi AR; Erstad BL; McBride A; Slack M; Abraham I
    Expert Opin Drug Saf; 2021 Apr; 20(4):489-497. PubMed ID: 33445985
    [No Abstract]   [Full Text] [Related]  

  • 19. Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study.
    Shimamura Y; Watanabe S; Maeda T; Abe K; Ogawa Y; Takizawa H
    Clin Exp Nephrol; 2021 May; 25(5):479-487. PubMed ID: 33471239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review.
    Nersesjan V; McWilliam O; Krarup LH; Kondziella D
    Neurology; 2021 Jul; 97(2):e191-e202. PubMed ID: 33952651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.